Explore By Subject Area   

Lead Editorial

Developing Checkpoint Inhibitors for Patients Who Don’t Respond to PD-1/CTLA-4

Developing Checkpoint Inhibitors for Patients Who Don’t Respond to PD-1/CTLA-4

Dr Tatiana Novobrantseva, Chief Scientific Officer, NextPoint Therapeutics, tells us about the work she’s leading to develop therapies that harness a new and differentiated member of the B7 family, for patients who didn’t see benefit from current checkpoint blockade therapies.

Read More

More Related Content

Editorial

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.